openPR Logo
Press release

Psoriasis Pipeline Outlook Report 2024 (Updated)

04-10-2024 08:12 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Psoriasis Pipeline

Psoriasis Pipeline

DelveInsight's, "Psoriasis Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Psoriasis Pipeline Report
• Over 80+ Psoriasis companies are evaluating 80+ Psoriasis pipeline therapies in various stages of development, and their anticipated acceptance in the Psoriasis market would significantly increase market revenue.
• The leading Psoriasis Companies working in the market include Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
• Promising Psoriasis Pipeline Therapies in the various stages of development include GN-037, Clobetasol 17-propionate, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, KX01 0.01% (0.1 mg/g), and others.
• April 2024: GEN İlaç ve Sağlık Ürünleri A.Ş. announced a study of Phase 2 clinical trials for GN-037 and Clobetasol 17-propionate. This Phase II study was designed as a multicenter, randomized, double-blind, placebo-controlled and 3-parallel arm, to assess clinical efficacy, safety, and tolerability of GN-037 versus clobetasol 17-propionate and placebo in patients diagnosed with mild to moderate plaque psoriasis at least 6 months ago.
• March 2024: Astellas Pharma Global Development Inc. announced a study of Phase 2 clinical trials for ASKP1240. The purpose of this study is to explore the safety and tolerability of multiple doses of ASKP1240 compared to placebo and determine Pharmacokinetics and Pharmacodynamics in subjects with moderate to severe psoriasis.

Request a sample and discover the recent advances in Psoriasis Treatment Drugs @ Psoriasis Infection Pipeline Outlook Report- https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Psoriasis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Psoriasis Overview
Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors. It is a non-contagious dermatosis disease affecting almost 2% of the world population. The percentage of body affected by psoriasis can vary on an individual basis.

Find out more about Psoriasis Treatment Landscape @ Drugs for Psoriasis Treatment- https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Psoriasis Emerging Drugs Profile

• Topical roflumilast: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). The therapy is in Phase III clinical development for the treatment of Plaque Psoriasis.

• GSK2982772: GlaxoSmithKline
GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. The molecule is in Phase I clinical development for the treatment of Psoriasis.

Psoriasis Pipeline Therapeutics Assessment
There are approx. 80+ key Psoriasis companies which are developing the therapies for Psoriasis. The Psoriasis companies which have their Psoriasis drug candidates in the most advanced stage, i.e. Registered include, Biocad.

DelveInsight's Psoriasis pipeline report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

The Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

Psoriasis Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Learn more about the emerging Psoriasis Pipeline Therapies @ Psoriasis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Psoriasis Pipeline Report
• Coverage- Global
• Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Psoriasis Companies- Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
• Psoriasis Pipeline Therapies- GN-037, Clobetasol 17-propionate, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, KX01 0.01% (0.1 mg/g), and others.

Dive deep into rich insights for new drugs for Psoriasis treatment, Visit @ Psoriasis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Psoriasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Psoriasis - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Psoriasis Collaboration Deals
9. Late Stage Products (Phase III)
10. CT-P43: Celltrion
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. EDP1815: Evelo Biosciences
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. AZD0284: AstraZeneca
17. Drug profiles in the detailed report…..
18. Early Stage Products (Preclinical)
19. AZD0284: AstraZeneca
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Psoriasis Key Companies
23. Psoriasis Key Products
24. Psoriasis- Unmet Needs
25. Psoriasis- Market Drivers and Barriers
26. Psoriasis- Future Perspectives and Conclusion
27. Psoriasis Analyst Views
28. Psoriasis Key Companies
29. Appendix

For further information on the Psoriasis pipeline therapeutics, reach out @ Psoriasis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Psoriasis Pipeline Outlook Report 2024 (Updated) here

News-ID: 3457981 • Views:

More Releases from DelveInsight Business Research LLP

Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols Therapeutics LLC, Arriva Pharmaceuticals, Inc., Takeda, Kamada Ltd, and others.
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report • The increase in Alpha-1 Protease Inhibitor Deficiency Market Size
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutiscs, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, Un
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Key Takeaways from the Amyloidosis Market Research Report • The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emerging Drugs | Sol-Gel Technologies, Ltd, Premier Research Group plc, PellePharm Inc., DUSA Pharmaceuticals, Inc., Ascend Biopharmaceuticals Inc., Genentech Inc., Palvella Therapeu
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report • The increase in Basal Cell Nevus Syndrome Market Size
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline ReportMirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, and others. Promising Biliary Atresia Therapies in the various stages of development include BYLVAY, LIVMARLI, and
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Key Takeaways from the Biliary Atresia Market Research Report • The increase in Biliary Atresia Market Size is a direct consequence of the increasing

All 5 Releases


More Releases for Psoriasis

Psoriasis Treatment Market for Acne and Psoriasis in North America and Europe: H …
A new research report highlighting the advances made in phototherapy treatment in North America and Europe has been added to the repository of Market Research Hub (MRH). The report titled “Phototherapy Treatment Market for Acne and Psoriasis: North America and Europe Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 – 2027” offers detailed insights and analysis on the key factors impacting the growth of the phototherapy treatment market for acne
Technological Advancements Of Psoriasis Market with Focus on Plaque Psoriasis 20 …
Albany, NY, 16th November : Recent research and the current scenario as well as future market potential of "Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020" globally. Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=748522 It
Global Psoriasis Industrial and Market Analysis with Focus on Plaque Psoriasis: …
"Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed
Psoriasis Treatment Market: Analysis & Trends 2024
Global Psoriasis Treatment Market - Overview This report on the Psoriasis Treatment market analyzes the current and future scenario of the global market. Approval of new biologics, increase in access for the treatment in developing market, increase in the number of psoriasis patients, are boosting the growth of the global Psoriasis Treatment market. Increase in the incidence of Psoriasis and skin disorders, and novel pipeline drugs are some of the factors
Psoriasis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Psoriasis - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis - Pipeline Review, H1 2017, provides an overview of the Psoriasis (Immunology) pipeline landscape. Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It